

# Development of an NMC Therapeutic Candidate Using a BRD4-NUT Degradator

InnoCure Therapeutics, Inc



ONCOLOGY	Candidate
Product Type	Synthetic Drugs, TPD (Targeted-Protein Degradation)
Indication	1 <sup>st</sup> indication : NUT midline carcinoma (NMC) 2 <sup>nd</sup> indication : MYCN amplified neuroblastoma, T-ALL, Myc-related cancer
Target	Bromodomain-containing protein 4-nuclear protein in testis (BRD4-NUT)
MoA(Mechanism of Action)	Degradation of BRD4-NUT in rare and highly aggressive NUT carcinoma
Competitiveness	<ol style="list-style-type: none"> <li>1. Global leader in BRD4-NUT degrader for NMC</li> <li>2. Enhanced oral formulation with improved pharmacokinetic (PK) profile achieved through increased binding affinity and structural analysis with E3 ligase</li> <li>3. Degradator showing superior in vitro and in vivo efficacies to those of inhibitors</li> <li>4. Overcoming the limitations of conventional BRD4-NUT inhibitors, such as resistance, toxicity, and ineffectiveness</li> <li>5. Applying InnoCure's ELCBIL technology to enhance the selectivity to the BRD4 among other BRD family</li> </ol>
Development Stage	Candidate
Route of Administration	PO (QD)